Author name: Leonardo Arias

Research released by the clinical AI company shows that its new dose verification tool outperformed general-use AI models, which it says are rife with errors. It’s Doximity’s latest play to stand out as major AI companies forge into healthcare.

M&A rose, but company valuations declined in the first half of 2026 compared with the year-ago period, according to EY’s Pulse of the Industry report.

The first-of-its-kind transcatheter device treats paravalvular leak after valve replacement surgery, to spare the patient from another open-heart surgery.

An increasing shift toward outpatient surgeries and slower-than-expected ramps to profitability at some of its hospitals dinged Universal Health Services’ earnings in the third quarter.

In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma raised its full-year revenue forecast.

Weeks after an investor called for leadership changes, Cooper has parted ways with its CEO and proposed a new-look board of directors.

On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations.

With the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline.

Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.

Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.